The DPP-4 inhibitors promote glucose-dependent insulin secretion, i.e., in the presence of lower blood glucose values, the insulin release is not expected, which contributes to reduce the risk of hypoglycemia[16]. The gene discussed is INS; the disease is Hypoglycemia.